Search

Displaying results 4061 - 4070 of 9693 in total
  1. Drug

    Anti-SARS-CoV-2 equine immunoglobulin fragments

    go.drugbank.com/drugs/DB16368
    Investigational

    Anti-SARS-CoV-2 equine immunoglobulin fragments, also known as INOSARS, is a polyvalent passive immunization being tested in the clinical trial NCT04514302 (Safety and Efficacy of Anti-SARS-CoV-2 Equine

  2. Drug

    Actoxumab

    go.drugbank.com/drugs/DB16376
    Investigational

    Actoxumab is under investigation in clinical trial NCT01241552 (A Study of MK-3415, MK-6072, and MK-3415A in Participants Receiving Antibiotic Therapy for Clostridium Difficile Infection (MK-3415A-001)

  3. Drug

    Axatilimab

    go.drugbank.com/drugs/DB16388
    ApprovedInvestigational

    Axatilimab is a humanized IgG4 monoclonal antibody produced in Chinese hamster ovary cells. … [L51194] It is targeted against macrophage colony-stimulating factor 1 receptor (CSF-1R), causing a reduction in circulating levels of monocytes and macrophages responsible for the symptoms associated

  4. Drug

    Mobocertinib

    go.drugbank.com/drugs/DB16390
    ApprovedInvestigationalWithdrawn

    Mobocertinib is a kinase inhibitor targeted against human epidermal growth factor receptor (EGFR). … It is used specifically in the treatment of non-small cell lung cancer (NSCLC) caused by exon 20 insertion mutations in the _EGFR_ gene,[L38368] which are typically associated with a poorer prognosis (

  5. Drug

    Efineptakin alfa

    go.drugbank.com/drugs/DB16395
    Investigational

    Compared to endogenous IL-7, NT-I7 is more stable and potent, has a longer half-life, and has better bioavailability. … Efineptakin alfa (also known as NT-I7) is a long-acting human interleukin-7 (IL-7) fusion protein that promotes T-cell development, contributing to the immune response.

    Synonyms: Recombinant human interleukin-7 fused to a hybrid crystallizable fragment region of a human antibody (Rhil-7-Hyfc), Recombinant human interleukin-7 fused to a hybrid crystallizable fragment region of a human antibody (rhIL-7-hyFc).
  6. Drug

    Efmarodocokin alfa

    go.drugbank.com/drugs/DB16398
    Investigational

    Efmarodocokin alfa is under investigation in clinical trial NCT04386616 (A Study to Evaluate the Safety and Efficacy of MSTT1041A (Astegolimab) or UTTR1147A in Patients With Severe COVID-19 Pneumonia).

  7. Drug

    Regdanvimab

    go.drugbank.com/drugs/DB16405
    ApprovedWithdrawn

    Trials investigating the use of regdanvimab as a therapeutic candidate for the treatment of COVID-19 began in mid-2020. … Regdanvimab (CT-P59) is a recombinant human IgG1 monoclonal antibody directed at the receptor binding domain (RBD) of the SARS-CoV-2 spike protein.

  8. Drug

    Azvudine

    go.drugbank.com/drugs/DB16407
    Investigational

    Azvudine is under investigation in clinical trial NCT04668235 (Study on Safety and Clinical Efficacy of AZVUDINE in COVID-19 Patients (Sars-cov-2 Infected)).

  9. Drug

    Tiragolumab

    go.drugbank.com/drugs/DB16409
    Investigational

    Tiragolumab is under investigation in clinical trial NCT04513925 (A Study of Atezolizumab and Tiragolumab Compared With Durvalumab in Participants With Locally Advanced, Unresectable Stage III Non-small

  10. Drug

    VXA-CoV2-1

    go.drugbank.com/drugs/DB16433
    Investigational

    VXA-CoV2-1 is a non-replicating adenoviral vector-based oral tableted vaccine candidate that expresses a SARS-CoV-2 antigen and dsRNA adjuvant[L30493].